Changes after publication

Changes after publication

February 2014: implementation section updated to clarify adalimumab, etanercept, infliximab, rituximab and abatacept are recommended as options for treating rheumatoid arthritis after the failure of a TNF inhibitor. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)